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Abstract
Modification of the furan ring of salvinorin A (1), the main active component of Salvia divinorum,
has resulted in novel neoclerodane diterpenes with opioid receptor affinity and activity.
Conversion of the furan ring to an aldehyde at the C-12 position (5) has allowed for the synthesis
of analogues with new carbon-carbon bonds at that position. Previous methods for forming these
bonds, such as Grignard and Stille conditions, have met with limited success. We report a
palladium catalyzed Liebeskind-Srogl cross-coupling reaction of a thioester and a boronic acid
that occurs at neutral pH and ambient temperature to produce ketone analogs at C-12. To the best
of our knowledge, this is the first reported usage of the Liebeskind-Srogl reaction to diversify a
natural product scaffold. We also describe a one-step protocol for the conversion of 1 to 12-epi-1
(3) through microwave irradiation. Previously, this synthetically challenging process has required
multiple steps. Additionally, we report in this study that alkene 9 and aromatic analogues 12, 19,
23, 25, and 26 were discovered to retain affinity and selectivity at kappa opioid receptors (KOP).
Finally, we report that the furan-2-yl analog of 1 (31) has similar affinity to 1. Collectively, these
findings suggest that different aromatic groups appended directly to the decalin core may be well
tolerated by KOP receptors, and may generate further ligands with affinity and activity at KOP
receptors.
1. Introduction
Psychoactive natural products have played a vital role in the development of treatments for a
number of diseases and have advanced our knowledge of basic biological processes in the
central nervous system (CNS).1 For example, the endogenous opioid and cannabinoid
receptor systems were discovered through the systematic study of psychoactive natural
products. In addition to the discovery of endogenous opioid and cannabinoid receptor
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systems, the investigation of psychoactive natural products has also led to the development
of useful biological probes that have advanced our knowledge of the underlying causes of
many CNS disorders.2 Furthermore, structural modifications of such natural products have
led to the development of effective medications to treat a number of CNS disorders.3
Presently, combinatorial-based approaches and genomics have largely replaced natural
products screening in CNS drug discovery. Even with these advances in technology, CNS
drugs entering clinical development have only approximately a 7% probability of reaching
the marketplace, as compared to an industry average of 15%.4–5 Thus, it is imperative to
find and explore new chemical scaffolds for CNS drug discovery and development, as well
as for potential probes that can be used to further enhance our understanding of
neurobiology.
One recent example of a psychoactive natural product is the neoclerodane diterpene,
salvinorin A (1) (Figure 1).4–7 This natural product is the main active component of the
hallucinogenic mint plant Salvia divinorum Epling & Játiva (Lamiaceae). Historically, S.
divinorum has been used by the Mazatec Indians of Oaxaca, Mexico in ethnomedicinal
practice.8 S. divinorum is notorious in the public eye for its use as a recreational drug.9, 10
Due to its hallucinogenic effects, several countries and states have scheduled S. divinorum
as a schedule I controlled substance. In 2002, the site of action of 1 was identified as opioid
(KOP) receptors where 1 acts as a high efficacy agonist.4 Furthermore, 1 appears to have
unique properties as a KOP receptor ligand that includes its high efficacy in particular
transduction systems and a reduced propensity to cause receptor desensitization.11, 12 These
findings suggest that 1 offers a new chemotype for the development of functionally selective
KOP ligands as biological probes.13 Additionally, 1 is structurally distinct from other known
opioid ligands such as U50,488 (2) in that it does not contain a basic nitrogen; a feature
traditional opioid pharmacology believed to be required.14–18
Currently available KOP receptor ligands, which have become of interest due to the
interaction of the KOP/dynorphin system with major neuropsychiatric disorders and
addiction, suffer from several therapeutic limitations. First, KOP agonists have been shown
to potentiate cocaine reward and produce psychotomimesis, sedation, and nausea.19–22 Thus,
high efficacy agonism at KOP results in behavioral toxicity and preclinical models support
its involvement in endogenous pathophysiology (e.g., anxiety, depression, and addiction).
Therefore, partial agonism or antagonism at KOP receptors is a valuable target for
medications development. Second, almost all currently available KOP antagonists have a
slow onset of action and are extremely long in duration of action.23, 24 This makes these
agents difficult to use in translational and pharmacokinetic models. Thus, there is a pressing
need to develop novel agents and biological probes devoid of these limitations.
One approach to overcoming the limitations of currently available KOP ligands is to identify
and develop new chemical scaffolds with improved drug-like characteristics.24–27 Another
approach is to modify a KOP selective natural product, such as 1, into a partial agonist or
antagonist through systematic structure-activity relationship studies. To this end, our present
investigation looked to answer three questions: (1) what is the effect of configuration of the
C-12 position on opioid affinity and activity; (2) can the affinity and/or activity be enhanced
from the addition of a suitable group off an aryl ketone analogue; and (3) what is the effect
of altering the position of the oxygen atom in the furan ring. Our results are described
herein.
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Salvinorin A (1) was isolated from S. divinorum and we developed a one-step protocol for
the conversion of 1 to 12-epi-1 (3) through microwave irradiation (Scheme 1). 2,4,4,6-
Tetrabromocyclohexa-2,5-dienone and 1 were dissolved in anhydrous, degassed
dichloromethane and irradiated in the microwave for 30 minutes at 130 °C. Purification via
column chromatography afforded 3 and 428 in 39% and 30% yields, respectively. Selective
olefination of 1 was envisioned by introduction of an aldehyde at C-12, exploiting the
reactivity of the aldehyde relative to the other four carbonyls present in 1 (Scheme 2).
Aldehyde 5 was obtained following our previously published methods.29 Several different
olefination reactions were attempted including Wittig and Horner-Wadsworth-Emmons
conditions. These methods were ineffective due to low yields, difficulties in purification,
and ultimately aldehyde degradation. In the end, success was found using Julia-Kocienski
olefination conditions. These conditions are applicable for use with base-sensitive aldehydes
and are milder than previously attempted olefination conditions. To obtain the needed Julia-
Kocienski precursor, synthesis was initiated with 3-furaldehyde that was reduced with
NaBH4 to yield the corresponding alcohol 6a in 88% yield. Alcohol 6a was then displaced
with bromine in 45% yield (6b) and treated with ammonium heptamolybdate tetrahydrate-
peroxide complex to afford the Julia-Kocienski precursor 7 in 86% yield.30 The reaction of
5 and 7 in the presence of KHMDS afforded alkenes 8 and 9 in overall reaction yield of
12%. The individual isomers were isolated by flash column chromatography followed by
additional HPLC purification in a 2:1 ratio of 8 to 9.
Additional furan-modified ketone analogues of 1 were synthesized as described in Scheme
3. Many different methods to form carbon-carbon bonds are known in the scientific
literature. However, many of these methods are not suitable to highly functionalized or acid/
base-sensitive compounds like 1.31 In our hands, Grignard reactions using aldehyde 5 were
met with limited success due to poor solubility of 5 in THF and ether at low temperatures
and resulted in low yields (0 – 20%). Béguin and coworkers were able to synthesize several
ketone derivatives through in situ formation of the acid chloride followed by Stille coupling
of stannanes in low to moderate yields (7 – 57%).32 This procedure is also limited by the
availability and difficulties associated with stannane reagents. To overcome these
challenges, an investigation into the suitability of the Liebeskind-Srogl reaction was
undertaken.33, 34 The Liebeskind-Srogl reaction is a palladium catalyzed cross-coupling
reaction of a thioester and boronic acid that requires a stoichometric amount of copper (I)
additive.27, 28 This reaction occurs at neutral pH and room temperature and has previously
been utilized on base sensitive substrates.35,36 Additionally, an increasing number of
boronic acids are commercially available, which further contributes to the convenience of
analogue synthesis. With a promising reactivity profile, the thiophenol ester at the C-12
position was synthesized using the same CDMT and N-methylmorpholine conditions
previously developed with substitution of ethanethiol for thiophenol.29 Thioester 11 was
synthesized in 62% yield. Using bis(dibenzylideneacetone)palladium (0), copper (I)
thiophene carboxylate, and triethylphosphite in anhydrous THF, coupling of thioester 11 and
desired boronic acids synthesized ketone derivatives 12 – 29 in 29 – 87% yields. Ketone
analogue 30 was synthesized as an intermediate towards the synthesis of a furan-2-yl
analogue of salvinorin A (Scheme 4). To access this compound, ketone analogue 30 was
refluxed with SeO2 in bromobenzene.37 The initial thought was to isolate the dicarbonyl and
use previously developed conditions to cyclize to the furan-2-yl analogue in a two-step
procedure.38 Fortuitously, cyclization also occurred under oxidative conditions to afford
analogue 31 in 18% yield from 30. To the best of our knowledge, this is the first report using
the Liebeskind-Srogl reaction to diversify a natural product scaffold.
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3. Results and Discussion
The synthesized compounds were evaluated for affinity and efficacy at opioid receptors
(Table 1).39 It was thought that the analogues prepared would provide greater insight into
the potential use of modified neoclerodanes as opioid receptor probes. Our investigation
initially began by addressing the effect of configuration at the C-12 position has on opioid
affinity and activity. It was envisioned that this alteration would further investigate the
amount of structural flexibility tolerated at the binding site of KOP receptors for
neoclerodanes. Inversion of this center is synthetically challenging as 1 is a highly
functionalized neoclerodane diterpene and has shown sensitivity to both acids and bases,31
however, 3 was synthesized by Béguin and coworkers in several steps and 19% overall
yield.32 NMR and independent X-ray crystallographic data (see supplemental material) were
consistent with the previous report. The mechanism for the apparent bond breaking and
reforming has not been fully elucidated and is currently under investigation. Compound 3
demonstrated similar affinity at KOP receptors to 1 (Ki = 7.4 ± 0.7 nM vs. Ki = 17 ± 1 nM).
In our hands, 3 had a 2-fold loss in affinity relative to 1 however, Béguin and coworkers
found 3 to have a greater loss in affinity relative to 1.32
To facilitate a greater understanding of the steric demands of the furan ring, analogues 8 and
9 were prepared. It was envisioned that the synthesis of these analogues would explore the
influence of the additional steric bulk in the furan binding site, as well as the preferred
orientation of the oxygen atom in the furan ring by constraining its rotation with the addition
of the olefin. It was found that the cis analogue 9 had almost 40-fold higher affinity for the
KOP receptor compared to the trans analogue 8 (Ki = 30 ± 4 nM vs. Ki = 1,120 ± 30 nM).
This finding suggests that size plays a key role in the binding of the furan ring substituent
given that the extended trans conformation (8) has weaker affinity compared to the cis
orientation (9). In addition, it appears that distance from the decalin core plays an important
role in the bonding of the furanyl oxygen of 1.
Previous investigations have suggested that modification or substitution of the furan ring is
tolerated but often diminishes affinity and efficacy at KOP receptors.29, 32, 39 To further
explore the potential replacement of the furan ring with other substituents, a series of aryl
ketone derivatives were synthesized. Our intention was to identify a more desirable
hydrogen bond interaction with the carbonyl and its KOP receptor binding site while
potentially accessing another favorable interaction in the binding pocket through judicious
choice of a substituent on the aryl ring. Initially, phenyl analogue 1232 was prepared and
found to have decreased affinity compared to 1 (Ki = 70 ± 3 nM vs. Ki = 7.4 ± 0.7 nM).
Based on the <100 nM affinity and the potential of this scaffold to have greater metabolic
stability than furan containing salvinorin A, investigations into the effects of substitutions at
the ortho, meta, and para positions were undertaken. Given the many potential possibilities,
we elected to selectively probe the effect of a methoxy group and a phenolic group. Our
rationale was that we could quickly gauge the role of electron donating properties, as well as
the possible effect of hydrogen bond donating compared to hydrogen bond accepting
properties on affinity. Introduction of a methoxy group (13 – 15) was found to generally
decrease affinity compared to 12. Of these substitutions, we identified that incorporation of a
m-methoxy group (14) was best tolerated (Ki = 290 ± 10 nM). Similarly, we found that
introduction of a phenol group (16 – 18) resulted in generally decreased affinity compared to
12. However, we found that a m-phenolic group was best tolerated and had comparable
affinity to 12 (Ki = 110 ± 5 nM vs. Ki = 70 ± 3 nM). Given that meta substitution was best
tolerated, we decided to explore additional meta substituents.
We first focused on preparing carboxamide analogue (19) as a nonclassical bioisosteric
replacement for the phenol group. Previously, Wentland and coworkers found that this
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structural modification resulted in high affinity analogues at opioid receptors when the 8-
position hydroxyl of cyclazocine was modified, as well as the 3-position of the morphinan
nucleus.40, 41 Remarkably, carboxamide (19) was identified as having increased affinity
approximately 3-fold compared to 17 (Ki = 40 ± 1 nM vs. 110 ± 5 nM). Given this finding,
we sought to further explore the nature of the increased affinity. Thus we prepared m-cyano
(20), m-trifluoromethoxy (21), and m-trifluoromethyl (22). The replacement of the
carboxamido group with a cyano moiety decreased affinity 6-fold compared to 19 (Ki = 220
± 10 nM vs. Ki = 40 ± 1 nM). Substitution with a trifluoromethoxy or a trifluoromethyl
group also decreased affinity compared to 19 (Ki > 10,000 nM and Ki = 2,260 ± 120 nM,
respectively vs. Ki = 40 ± 1 nM). These latter findings suggest that the electron withdrawing
nature of the carboxamido group is not responsible for the increase in affinity. However,
additional analogues will need to be prepared to more definitively prove this point.
The effect of replacing the phenyl group of 12 was also investigated. These analogues were
designed to probe the potential of replacing the benzene ring with several different
bioisosteric replacements as well as the necessity of an aromatic ring. The substitution of the
benzene ring with a 2-furan (23)32 and 3-furan (24) ketone was probed. These changes were
well tolerated as 23 and 24 were found to have similar affinity to 12 (Ki = 80 nM and Ki =
150 ± 10 nM, respectively vs. Ki = 70 ± 3 nM). Given this success, we probed additional
replacements of the benzene ring. The substitutions of the phenyl ring with a 2-thiophene
(25)32 and 3-thiophene (26) were found to increase affinity at KOP receptors compared to
12 (25:Ki = 36 ± 2 nM, 26:Ki = 31 ± 3 nM vs. 12: Ki = 70 ± 3 nM). We then sought to
further explore size requirements for the aromatic substituent. To this end, we annulated an
additional benzene ring onto 23 (27), 25 (28), and 26 (29). Unfortunately, these changes
were not well tolerated and affinity was considerably decreased (27: Ki > 10,000 nM; 28: Ki
= 9,210 nM and 29: Ki > 10,000 nM). Finally, the necessity of the phenyl was probed by
replacing it with a cis-propenyl group (30). This change was not well tolerated and led to a
4-fold decrease in affinity compared to 12 (Ki = 320 ± 20 vs. Ki = 70 ± 3 nM). This latter
finding is interesting and suggests that an aromatic ring may not be completely necessary for
affinity. However, additional alkyl analogues will need to be prepared to confirm this
hypothesis. Collectively, these results suggest that affinity of 12 may be enhanced by the
introduction of m-carboxamido group (19) or through bioisosteric replacement of the phenyl
ring (23, 25, and 26).
Interestingly, 23 was found previously to have reduced affinity compared to the present
investigation (Ki > 1,000 nM vs. K = 80 nM).32 The previous report suggested that the lack
of affinity seen by 23 might be the result of instability under the assay conditions.32
However, we saw no evidence of stability issues and this may explain the increase in
affinity. Another possibility may be the presence of trace impurities not seen in the present
investigation. One potential source of impurities is tin byproducts as the previous
investigation used Stille coupling conditions.32 Our present investigation did not use this
type of coupling favoring a more “green” method.
Next, we sought to determine the effect of removing the ketone spacer in 23 (31). Our other
motivation was this analogue would provide information on the importance of the position
of the oxygen in the furan ring of 1 on opioid receptor affinity. Several molecular modeling
studies have suggested that the oxygen of the furan ring is directly participating in a
hydrogen bond with the KOP receptor.4, 42 It was envisioned that significant changes in
affinity between 1 and 31 would validate the importance of the hydrogen bond between the
furanyl oxygen and the KOP receptor. The removal of the ketone spacer resulted in a 9-fold
increase in affinity at KOP receptors compared to 23 (Ki = 8.7 ± 0.4 nM vs. Ki = 80 ± 4
nM). This finding suggests that other modifications to the furan ring of 1 may also be
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tolerated. While synthetic methods exist for their preparation,43, 44 their use for structure-
activity relationship studies have not been described to date.
Surprisingly, 31 was found to have almost identical affinity at KOP receptors compared to 1
(Ki = 8.7 ± 0.4 nM vs. Ki = 7.4 ± 0.7 nM, respectively). This would suggest that a hydrogen
bond exists from the furanyl oxygen of 31 to the same residue on the KOP receptor as the
furanyl oxygen of 1. Due to the lack of 1 – KOP receptor co-crystal structure, one way to
investigate the possibility of a hydrogen bond is through mutation of residues of the KOP
receptor thought to be involved in the binding of 1 and observation of the changes to
affinity. However, this is beyond the scope of the present investigation.
Selected analogues were then evaluated for their efficacy at KOP receptors using the
[35S]GTP-γ-S assay (Table 2). 12-Epi-1(3) was found to be 18-fold less potent than the 1
(EC50 = 720 ± 97, Emax = 109 ± 4% vs. EC50 = 40 ± 6 nM, Emax = 124 ± 6%). Despite its
high affinity, 9 was found to have reduced potency as an agonist in the [35S]GTP-γ-S assay
compared to 1 (EC50= 1,370 ± 180 nM vs. EC50 = 40 ± 6 nM). The reasons for this large
discrepancy are unclear but may be due to poor solubility under the assay conditions. Phenyl
ketone 12 was found to be a partial agonist compared to 1 (Emax= 74 ± 6 vs. Emax = 124 ±
6). However, its reduced potency (EC50 = 1370 ± 180 nM vs. EC50 = 40 ± 6 nM) inhibits its
utility as a pharmacological probe. Carboxamide 19 was found to have 18-fold reduced
potency in the [35S]GTP-γ-S read assay compared to 1 (EC50 = 730 ± 90 nM vs. EC50 = 40
± 6 nM). While there was little difference in affinity for KOP receptors, 26 was found to be
approximately 3-fold more potent than 25 (EC50 = 620 ± 50 nM vs. EC50 = 1,630 ± 23 nM)
as an agonist. The most potent compound identified in the [35S]GTP-γ-S assay was 2-
furanyl analogue 31 (EC50 = 140 ± 10 nM). Compound 31 was found to be 3-fold less
potent than 1 as an agonist.
Given these results, we elected to further profile 1, 19 and 31 as KOP agonists using the
fluorescent Ca2+ mobilization assay (Table 3). While this particular assay is a more artificial
system, it was envisioned that an additional assay would provide insight into the
pharmacological properties of these neoclerodanes. In particular, it was thought that this
assay would provide further validation of the partial agonist character of 19 and 31 when
compared to 1 in the [35S]GTP-γ-S assay. As seen in the [35S]GTP-γ-S assay, carboxamide
19 was found to have reduced potency compared to 1 (EC50 = 75.4 ± 21 nM vs. EC50 = 6.11
± 0.04 nM). However, 19 was found to possess identical efficacy compared to 1 (Emax = 97
± 2 vs. Emax = 97 ± 5). This finding suggests that the partial agonism seen in the [35S]GTP-
γ-S assay may not be readily translatable to other assays. However, this supposition needs
further testing. Also as seen previously, the movement of the furanyl oxygen from the 3-
position (1) to the 2-position (31) resulted in a 2-fold decrease in potency (EC50 = 12.2 ± 4.4
nM vs. EC50 = 6.11 ± 0.04 nM). Moreover, 31 was found to have similar efficacy to 1 (Emax
= 97 ± 2 vs. Emax = 97 ± 8). Collectively these results suggest that the use of several
different assays will be necessary to best determine partial agonist activity for KOP
receptors.
Finally, we sought to explore the effects of 3 in nonhuman primates (Macaca mulatta) using
a neuroendocrine biomarker assay compared to 1.45 This assay has been previously used to
determine potency and apparent efficacy of structurally diverse KOP ligands, and is of
translational value since it can be used in rodents, non-human primates, and humans.46, 47
Previous reports have described 3 as a partial agonist when evaluated in the [35S]GTP-γ-S
assay (EC50 = 41 ± 6, Emax = 73 ± 6 compared to 2).32 A more recent study describes 3 as a
full agonist using the β-arrestin 2 DiscoveRx assay (EC50 = 382 ± 85, Emax = 126 ± 10
compared to 1).48 The differences in the agonist efficacy seen for 3 are likely due to
differences in receptor expression level, G-protein signaling, and other cell type dependent
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changes. As seen in Figure 2, the dose-effect curve for 3 is parallel to that of 1 in this assay,
but is rightward-shifted by approximately 10-fold (ED50 values from mean log dose-effect
curves were 0.038 and 0.0037 mg/kg, for 3 and 1, respectively). Therefore, while 3 has
lower potency than 1, there is no clear indication that it is acting as a partial agonist in this in
vivo assay, up to the largest dose that could be studied due to solubility limits.
4. Conclusions
In efforts to further elucidate the pharmacophore and structure-activity relationships of
neoclerodanes at opioid receptors, several furan-modified analogues were synthesized and
evaluated. We have developed a one-step protocol for the conversion of 1 to 12-epi-1 (3)
through microwave irradiation. This methodology should be valuable for further research
into the structure-activity relationships of neoclerodanes. We have described to the best of
our knowledge, the first reported use of the Liebeskind-Srogl reaction to modify a natural
product. Our results show that the insertion of a cis alkene spacer to 1 (9) is better tolerated
sterically at the binding site compared to a trans alkene spacer (8). Affinity for KOP
receptors can be maintained by replacing the furan ring with a phenyl ketone (12).
Additional structure-activity relationship studies have shown that affinity of 12 may be
enhanced by the introduction of m-carboxamido group (19) or through bioisosteric
replacement of the phenyl ring (23, 25, and 26). Surprisingly, 31 was found to have almost
identical affinity at KOP receptors compared to 1 (Ki = 8.7 ± 0.4 nM vs. Ki = 7.4 ± 0.7 nM,
respectively). This would suggest that a hydrogen bond exists from the furanyl oxygen of 31
to the same residue on the KOP receptor as the furanyl oxygen of 1. This finding also
suggests that other modifications to the furan ring of 1 may be well tolerated by KOP
receptors. Collectively, our results provide further evidence that modification of the furan
ring is tolerated and produces analogues with affinity and activity at KOP receptors. Further
evaluation of analogue 31 is currently underway and will be reported in due course.
5. Experimental Section
Unless otherwise indicated, all reagents were purchased from commercial suppliers and
were used without further purification. Melting points were determined on a Thomas-
Hoover capillary melting apparatus. NMR spectra were recorded on a Bruker DRX-400 with
qnp probe or a Bruker AV-500 with cryoprobe using values in ppm (TMS as internal
standard) and J (Hz) assignments of 1H resonance coupling. High resolution mass
spectrometry data were collected on either a LCT Premier (Waters Corp., Milford, MA)
time of flight mass spectrometer or an Agilent 6890 N gas chromatograph in conjunction
with a quarto Micro GC mass spectrometer (Micromass Ltd, Manchester UK). Thin-layer
chromatography (TLC) was performed on 0.25 mm plates Analtech GHLF silica gel plates
using ethyl acetate/n-hexanes, in 1:1 ratio as the solvent system unless otherwise noted.
Spots on TLC were visualized by UV (254 or 365 nm), if applicable, and phosphomolybdic
acid in ethanol. Column chromatography was performed with Silica Gel (32 – 63 μ particle
size) from MP Biomedical (Solon, OH). Analytical HPLC was carried out on an Agilent
1100 Series Capillary HPLC system with diode array detection at 209.4 nm on an Agilent
Eclipse XDB-C18 column (250 × 10 mm, 5 μm) with isocratic elution in 60% CH3CN/40%
H2O at a flow rate of 5.0 mL/min unless otherwise noted, or on a Phenomenex Luna C18
column (250 × 10 mm, 5 μm) with isocratic elution in 60% CH3CN/40% H2O unless
otherwise noted. The systematic name for salvinorin A (1) is (2S,4aR,6aR,7R,9S,10aS,
10bR)-methyl 9-acetoxy-2-(furan-3-yl)-6a,10b-dimethyl-4,10-dioxo-dodecahydro-1H-
benzo[f]iso-chromene-7-carboxylate. Salvinorin A was isolated from S. divinorum as
previously described.49
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5.1. Preparation of (2R,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-acetoxy-2-(furan-3-yl)-6a,10b-
dimethyl-4,10-dioxododecahydro-1H-benzo[f]isochromene-7-carboxylate (3)
In a 20 mL microwave tube, a solution of 1 (100 mg, 0.231 mmol, 1 equiv) in anhydrous
CH2Cl2 (15 mL), 2,4,4,6-tetrabromocyclohexa-2,5-dienone (113.7 mg, 0.277 mmol, 1.2
equiv) was added. The tube was sealed and irradiated in the microwave for 30 minutes at
130 °C. Solvent was removed under reduced pressure and the resulting residue was purified
via column chromatography using ethyl acetate, MTBE, and n-hexanes to afford 29 mg
(39% yield borsm) as a white solid. HPLC t = 11.463 min; purity = 96.07%. The 1H and 13C
spectra in CDCl3, melting point, and HRMS of 3 were as previously reported.32 X-ray
diffraction quality crystals were prepared by recrystallizing 3 from a mixture of EtOAc/ n-
hexanes.
5.2. Preparation of (4aR,6aR,7R,9S,10aS,10bR)-methyl 9-acetoxy-2-((E)-2-(furan-3-
yl)vinyl)-6a,10bdimethyl-4,10-dioxododecahydro-1H-benzo[f]isochromene-7-carboxylate
(8) and (4aR,6aR,7R,9S,10aS,10bR)-methyl 9-acetoxy-2-((Z)-2-(furan-3-yl)vinyl)-6a,10b-
dimethyl-4,10-dioxododecahydro-1H-benzo[f]isochromene-7-carboxylate (9)
KHMDS (1.64 mL of a 0.5 M solution in toluene, 0.83 mmol) was added in a dropwise
manner to a cooled (−78 °C) solution of 730(263 mg, 0.91 mmol) in THF (9 mL). After 30
min, a cooled solution of aldehyde 5 (300 mg, 0.761 mmol) in THF (20 mL) was added in a
dropwise manner over 3 minutes. The reaction mixture was stirred at −78 °C for 2 hours or
until completion and then it was diluted with EtOAc (9 mL) and quenched by the addition of
H2O (10 mL). After warming to room temperature over 30 min, the phases were separated
and the aqueous phase was extracted with EtOAc (2 × 10 mL). The combined organic
extracts were washed with brine (2 × 10 mL) and dried over Na2SO4. Filtration and
concentration under reduced pressure afforded 8 and 9 as a 2:1 mixture, which was
separated by flash column chromatography to afford, in order of elution, major isomer 8 as a
white solid and the minor isomer 9 also as a white solid. The minor isomer was further
purified by HPLC (40% CH3CN/60% H2O) on an Agilent Eclipse XDB-C18 column (250 ×
10 mm, 5 μm) at a flow rate of 5 mL/min.
8: Isolated as an off-white solid (25 mg, 7.2% yield) of trans isomer after purification; mp =
192 – 194°C; 1H NMR (500 MHz, CDCl3) δ 7.45 (s, 1H), 7.39 (s, 1H), 6.51 (d, J = 13.0 Hz,
2H), 5.88 (dd, J = 6.3, 15.8 Hz, 1H), 5.15 (d, J = 9.7 Hz, 2H), 3.76 (s, 3H), 2.77 (d, J = 8.1
Hz, 1H), 2.43 (d, J = 8.3 Hz, 1H), 2.34 (d, J = 9.9 Hz, 2H), 2.20 (s, 3H), 2.18 (s, 1H), 2.05
(s, 1H), 1.84 (s, 1H), 1.63 (s, 3H), 1.45 (s, 3H), 1.14 (s, 3H). 13C NMR (126 MHz, CDCl3) δ
201.85, 171.38, 171.06, 169.84, 143.57, 141.07, 126.66, 122.82, 121.74, 107.15, 77.40,
74.92, 63.96, 53.46, 51.82, 51.17, 42.89, 41.96, 38.05, 35.17, 30.56, 20.40, 17.95, 16.19,
15.04. HRMS (m/z): [M+Na] calcd for C25H30O8Na, 481.1838; found, 481.1832. HPLC tR=
8.832 min; purity = 98.21%.
9: Isolated as a white solid (15 mg, 4.3% yield) of cis isomer after purification; mp = 182 –
184 °C. 1H NMR (500 MHz, CDCl3) δ 7.52 (s, 1H), 7.45 (s, 1H), 6.45 (s, 1H), 6.40 (d, J =
11.2 Hz, 1H), 5.54 (d, J = 11.2 Hz, 1H), 5.47 – 5.41 (m, 1H), 5.20 – 5.15 (m, 1H), 3.76 (s,
3H), 2.81 – 2.75 (m, 1H), 2.34 (d, J = 9.9 Hz, 4H), 2.20 (s, 3H), 2.18 (s, 1H), 2.09 – 2.04 (m,
1H), 1.84 – 1.79 (m, 1H), 1.63 (s, 3H), 1.45 (s, 3H), 1.14 (s, 3H). 13C NMR (126 MHz,
CDCl3) δ 202.14, 171.81, 171.47, 170.21, 143.76, 142.04, 128.49, 124.02, 121.01, 110.94,
75.23, 74.12, 64.36, 53.84, 52.23, 51.65, 43.04, 42.30, 38.44, 35.70, 30.99, 20.83, 18.36,
16.65, 15.52. HRMS (m/z): [M+Na] calcd for C25H30O8Na, 481. 1838; found, 481.1830.
HPLC tR= 8.691 min; purity = 100%.
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5.3. Preparation of (2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-acetoxy-6a,10b-dimethyl-4,10-
dioxo-2-(phenyl-thiocarbonyl)dodecahydro-1H-benzo[f]isochromene-7-carboxylate (11)
To an oven dried round bottom flask under argon was added acid 1028 (0.64 g, 1.57 mmol, 1
equiv), CDMT (0.84 g, 4.72 mmol, 3 equiv), N-methylmorpholine (1.04 mL, 9.44 mmol, 6
equiv) followed by the addition of anhydrous THF (20 mL). After 1 hour, thiophenol (0.48
mL, 4.72 mmol, 3 equiv) was added and reaction stirred at room temperature for 48 hours.
The reaction was quenched with H2O (25 mL) and extracted with Et2O (3 × 30 mL). The
combined Et2O portion was washed with saturated aqueous NaHCO3 (3 × 20 mL), 2N HCl
(3 × 20 mL), brine (3 × 20 mL), and dried over anhydrous Na2SO4. The solvent was
evaporated in vacuo and the resulting residue purified by flash column chromatography on
silica gel using mixtures of EtOAc/n-hexanes and triturated in EtOAc/n-hexanes to afford
0.4912 g (62% yield) of 11 as a white solid, mp 136 – 140 °C; 1H NMR (500 MHz, CDCl3)
δ 7.47 – 7.38 (m, 5H), 5.14 (dd, J = 8.6, 11.6 Hz, 1H), 5.09 (dd, J = 7.2, 9.6 Hz, 1H), 3.72 (s,
3H), 2.74 (dd, J = 5.2, 11.6 Hz, 1H), 2.65 (dd, J = 7.2, 13.7 Hz, 1H), 2.37 – 2.22 (m, 2H),
2.22 – 2.10 (m, 6H), 1.84 – 1.74 (m, 1H), 1.74 – 1.50 (m, 3H), 1.39 (s, 3H), 1.09 (s,
3H). 13C NMR (126 MHz, CDCl3) δ 201.80, 197.76, 171.71, 170.01, 169.87, 134.91,
130.09, 129.62, 126.07, 80.51, 75.03, 64.39, 53.56, 52.21, 50.64, 42.17, 39.52, 37.96, 35.68,
30.89, 20.77, 18.38, 16.38, 16.20. HRMS (m/z): [M+H] calcd for C26H31O8S, 503.1740;
found 503.1720. HPLC tR = 8.507 min; purity = >99.99%.
5.4. General Procedure for Boronic Acid Coupling
A solution of 11 (1 equiv), appropriate boronic acid (3 equiv), copper (I) thiophene-2-
carboxylate (1.5 equiv), and bis(dibenzylideneacetone)palladium(0) (5 mol %) in anhydrous
THF under argon was stirred at room temperature. To the stirring solution, triethylphosphite
(20 mol %) was added. The reaction mixture was stirred at room temperature and monitored
by TLC until complete. Reactions were typically complete in 2 – 5 hours. The mixture was
then washed with saturated aqueous NaHCO3 (3 × 15 mL), brine (15 mL) and dried over
anhydrous Na2SO4. The solvent was evaporated in vacuo and the resulting residue purified
by flash column chromatography on silica gel using mixtures of EtOAc/n-hexanes and
triturated in EtOAc/n-hexanes to afford the desired product.
5.4.1. (2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-acetoxy-2-benzoyl-6a,10b-
dimethyl-4,10-dioxododecahydro-1H-benzo[f]isochromene-7-carboxylate (12)
—Compound 12 was synthesized from compound 11 using the general procedure and
phenylboronic acid to afford 0.221 g (82.4%) isolated as an off-white solid, mp = 164 – 167
°C. HRMS (m/z): [M+Na] calcd for C26H30O8Na, 493.1838; found 493.1819. HPLC tR =




benzo[f]isochromene-7-carboxylate (13)—Compound 13 was synthesized from
compound 11 using the general procedure and 2-methoxyphenylboronic acid to afford 0.082
g (66.2%) isolated as a white solid, mp = 186 – 188 °C. 1H NMR (500 MHz, CDCl3) δ 7.79
(dd, J = 1.8, 7.8 Hz, 1H), 7.56 – 7.47 (m, 1H), 7.07 – 6.99 (m, 1H), 6.96 (d, J = 8.2 Hz, 1H),
5.89 (t, J = 8.1 Hz, 1H), 5.10 – 5.02 (m, 1H), 3.92 (s, 3H), 3.69 (s, 3H), 2.75 – 2.63 (m, 2H),
2.30 – 2.19 (m, 2H), 2.16 – 2.06 (m, 6H), 1.72 (dt, J = 3.2, 13.3 Hz, 1H), 1.68 – 1.46 (m,
3H), 1.40 (s, 3H), 1.05 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 202.11, 197.37, 171.83,
171.72, 169.99, 159.03, 135.43, 131.80, 124.34, 121.47, 112.15, 79.32, 75.08, 65.20, 55.96,
53.51, 52.16, 49.69, 42.24, 38.20, 38.08, 35.76, 30.96, 20.84, 18.51, 16.90, 16.26. HRMS
(m/z): [M+NH4] calcd for C27H36O9N, 518.2390; found 518.2369. HPLC tR = 6.040 min;
purity = >99.99%
Lovell et al. Page 9















benzo[f]isochromene-7-carboxylate (14)—Compound 14 was synthesized from
compound 11 using the general procedure and 3-methoxyphenylboronic acid to afford 0.093
g (60.9%) isolated as a white solid, mp = 162 – 164 °C. 1H NMR (500 MHz, CDCl3) δ 7.48
– 7.43 (m, 2H), 7.40 (dd, J = 5.8, 10.3 Hz, 1H), 7.16 (ddd, J = 1.1, 2.6, 8.1 Hz, 1H), 5.86 (t, J
= 8.3 Hz, 1H), 5.16 – 5.06 (m, 1H), 3.86 (s, 3H), 3.72 (s, 3H), 2.77 – 2.61 (m, 2H), 2.28 (dd,
J = 7.1, 13.5 Hz, 2H), 2.20 – 2.09 (m, 6H), 1.80 – 1.73 (m, 1H), 1.67 (dt, J = 8.0, 14.9 Hz,
1H), 1.62 – 1.52 (m, 2H), 1.46 (s, 3H), 1.08 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 202.16,
195.34, 171.78, 171.14, 170.04, 160.31, 134.96, 130.32, 121.55, 121.08, 113.35, 75.51,
75.04, 65.02, 55.72, 53.45, 52.18, 49.49, 42.19, 38.59, 37.92, 35.79, 30.89, 20.80, 18.46,
16.93, 16.21. HRMS (m/z): [M+H] calcd for C27H33O9, 501.2125; found 501.2112. HPLC
tR = 6.217 min; purity = 99.03%.
5.4.4. (2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-acetoxy-2-(4-
methoxybenzoyl)-6a,10b-dimethyl-4,10-dioxododecahydro-1H-
benzo[f]isochromene-7-carboxylate (15)—Compound 15 was synthesized from
compound 11 using the general procedure and 4-methoxyphenylboronic acid to afford 0.069
g (50.7%) isolated as a white solid, mp = 117 – 120 °C. 1H NMR (500 MHz, CDCl3) δ 7.90
– 7.85 (m, 2H), 6.97 – 6.91 (m, 2H), 5.81 (t, J = 8.2 Hz, 1H), 5.14 – 5.01 (m, 1H), 3.87 (d, J
= 7.1 Hz, 3H), 3.69 (s, 3H), 2.74 – 2.65 (m, 1H), 2.62 (dd, J = 8.7, 13.6 Hz, 1H), 2.25 (dd, J
= 6.7, 13.8 Hz, 2H), 2.20 – 2.05 (m, 6H), 1.75 – 1.47 (m, 4H), 1.43 (s, 3H), 1.05 (s, 3H). 13C
NMR (126 MHz, CDCl3) δ 202.25, 193.81, 171.82, 171.36, 170.07, 164.65, 131.56, 126.54,
114.55, 75.19, 75.08, 65.08, 55.81, 53.45, 52.18, 49.37, 42.21, 38.59, 37.93, 35.73, 30.90,
20.81, 18.47, 17.08, 16.20. HRMS (m/z): [M+NH4] calcd for C27H36O9N, 518.2390; found
518.2379. HPLC tR = 6.247 min; purity = 96.68%.
5.4.5. (2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-acetoxy-2-(2-
hydroxybenzoyl)-6a,10b-dimethyl-4,10-dioxododecahydro-1H-
benzo[f]isochromene-7-carboxylate (16)—Compound 16 was synthesized from
compound 11 using the general procedure and 2-hydroxybenzeneboronic acid to afford
0.090 g (44.0%) isolated as a white solid, mp = 200 – 203 °C. 1H NMR (500 MHz, CDCl3)
δ 11.73 (s, 1H), 7.58 (d, J = 8.1 Hz, 1H), 7.53 (t, J = 7.8 Hz, 1H), 7.03 (d, J = 8.5 Hz, 1H),
6.95 (t, J = 7.6 Hz, 1H), 5.92 (t, J = 8.4 Hz, 1H), 5.10 (t, J = 10.0 Hz, 1H), 3.72 (s, 3H), 2.72
(dd, J = 8.7, 13.8 Hz, 2H), 2.28 (dd, J = 6.8, 13.4 Hz, 2H), 2.23 – 2.09 (m, 6H), 1.84 – 1.56
(m, 4H), 1.47 (s, 3H), 1.09 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 202.20, 200.58, 171.74,
170.98, 170.06, 163.70, 137.98, 129.64, 119.97, 119.25, 116.55, 75.08, 74.43, 64.96, 53.46,
52.22, 49.49, 42.23, 38.94, 37.93, 35.83, 30.88, 20.79, 18.49, 16.82, 16.22. HRMS (m/z):




benzo[f]isochromene-7-carboxylate (17)—Compound 17 was synthesized from
compound 11 using the general procedure and 3-hydroxyphenylboronic acid to afford 0.033
g (28.9%) isolated as a white solid, mp = 131 – 135 °C. 1H NMR (500 MHz, CDCl3) δ 7.23
(t, J = 7.9 Hz, 1H), 7.16 – 7.12 (m, 1H), 7.10 (d, J = 7.8 Hz, 1H), 6.96 (s, 1H), 6.92 (dd, J =
1.9, 8.1 Hz, 1H), 5.78 (dd, J = 6.9, 10.2 Hz, 1H), 5.17 (dd, J = 8.0, 12.1 Hz, 1H), 3.73 (d, J =
2.0, 3H), 3.00 – 2.89 (m, 2H), 2.82 (dd, J = 10.3, 13.4 Hz, 1H), 2.37 – 2.25 (m, 2H), 2.21 (s,
3H), 2.19 – 2.09 (m, 2H), 1.84 (d, J = 9.8 Hz, 1H), 1.78 – 1.62 (m, 3H), 1.48 (s, 3H), 1.07 (s,
3H). 13C NMR (126 MHz, CDCl3) δ 202.84, 196.51, 172.04, 171.73, 171.59, 157.11,
133.45, 130.47, 122.70, 120.61, 114.06, 76.42, 75.37, 63.95, 52.94, 52.19, 48.83, 42.71,
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38.75, 37.79, 35.85, 30.81, 21.00, 18.82, 17.22, 16.13. HRMS (m/z): [M–H] calcd for
C26H29O9, 485.1812; found 485.1801. HPLC tR = 4.286 min; purity = 99.66%.
5.4.7. (2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-acetoxy-2-(4-
hydroxybenzoyl)-6a,10b-dimethyl-4,10-dioxododecahydro-1H-
benzo[f]isochromene-7-carboxylate (18)—Compound 18 was synthesized from
compound 11 using the general procedure and 4-hydroxyphenylboronic acid to afford 0.092
g (68.0%) isolated as a white solid, mp = 232 – 236 °C. 1H NMR (500 MHz, CDCl3) δ 7.82
(d, J = 8.8 Hz, 2H), 6.85 (d, J = 8.8 Hz, 2H), 6.16 (s, 1H), 5.80 (t, J = 8.3 Hz, 1H), 5.13 –
5.08 (m, 1H), 3.72 (s, 3H), 2.72 (d, J = 7.7 Hz, 1H), 2.62 (dd, J = 8.7, 13.6 Hz, 1H), 2.30 (d,
J = 10.7 Hz, 2H), 2.20 (s, 1H), 2.17 (s, 5H), 1.79 – 1.52 (m, 4H), 1.45 (s, 3H), 1.08 (s,
3H). 13C NMR (126 MHz, CDCl3) δ 202.27, 193.59, 171.80, 171.60, 170.41, 161.34,
131.84, 126.60, 116.09, 77.44, 75.25, 65.01, 53.45, 52.21, 49.43, 42.25, 38.48, 37.94, 35.71,
30.88, 20.85, 18.46, 17.06, 16.23. HRMS (m/z): M–H] calcd for C26H29O9, 485.1812;
found 485.1783. HPLC tR = 4.624 min; purity = 95.63%.
5.4.8. (2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-acetoxy-2-(3-
carbamoylbenzoyl)-6a,10b-dimethyl-4,10-dioxododecahydro-1H-
benzo[f]isochromene-7-carboxylate (19)—Compound 19 was synthesized from
compound 11 using the general procedure and 3-aminocarbonylphenylboronic acid to afford
0.062 g (37.8%) isolated as a white solid, mp = 148 – 152 °C. 1H NMR (500 MHz, CDCl3)
δ 8.30 (s, 1H), 8.07 (d, J = 7.8 Hz, 1H), 8.02 (d, J = 7.9 Hz, 1H), 7.58 (t, J = 7.8 Hz, 1H),
6.52 – 6.31 (m, 1H), 5.88 (t, J = 8.4 Hz, 1H), 5.84 – 5.65 (m, 1H), 5.18 – 5.11 (m, 1H), 3.72
(s, 3H), 2.82 – 2.73 (m, 1H), 2.65 (dd, J = 8.4, 13.6 Hz, 1H), 2.28 (dd, J = 7.3, 13.3 Hz, 3H),
2.20 – 2.09 (m, 5H), 1.78 (d, J = 13.0 Hz, 1H), 1.75 – 1.54 (m, 3H), 1.47 (s, 3H), 1.09 (s,
3H). 13C NMR (126 MHz, CDCl3) δ 202.32, 194.95, 171.81, 170.95, 170.22, 168.05,
134.59, 133.96, 133.38, 132.26, 129.75, 127.79, 75.66, 75.18, 64.74, 53.40, 52.20, 49.71,
42.24, 38.11, 37.91, 35.78, 30.90, 20.82, 18.49, 16.87, 16.27. HRMS (m/z): [M+Na] calcd
for C27H31NO9Na, 536.1897; found 536.1901. HPLC tR = 3.465 min; purity = 96.22%
using 40% CH3CN:60% H2O as the mobile phase.
5.4.9. (2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-acetoxy-2-(3-cyanobenzoyl)-6a,
10b-dimethyl-4,10-dioxododecahydro-1H-benzo[f]isochromene-7-carboxylate
(20)—Compound 20 was synthesized from compound 11 using the general procedure and
3-cyanophenylboronic acid to afford 0.055 g (43.9%) isolated as a white solid, mp = 124 –
127 °C. 1H NMR (500 MHz, CDCl3) δ 8.25 (t, J = 1.4 Hz, 1H), 8.18 – 8.14 (m, 1H), 7.92 –
7.88 (m, 1H), 7.66 (t, J = 7.8 Hz, 1H), 5.79 (t, J = 8.3 Hz, 1H), 5.18 – 5.10 (m, 1H), 3.72 (s,
3H), 2.80 – 2.71 (m, 1H), 2.58 (dd, J = 7.9, 13.7 Hz, 1H), 2.35 – 2.26 (m, 2H), 2.21 (s, 1H),
2.20 – 2.08 (m, 5H), 1.82 – 1.52 (m, 4H), 1.48 (s, 3H), 1.10 (s, 3H). 13C NMR (126 MHz,
CDCl3) δ 202.11, 193.43, 171.71, 170.42, 170.09, 137.18, 134.85, 133.13, 132.96, 130.28,
117.76, 113.99, 75.65, 75.05, 64.78, 53.49, 52.22, 50.01, 42.18, 37.90, 37.64, 35.72, 30.88,
20.80, 18.41, 16.77, 16.30. HRMS (m/z): [M–H] calcd for C27H28NO8, 494.1815; found
494.1806. HPLC tR = 6.510 min; purity = 95.94%.
5.4.10. (2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-acetoxy-6a,10b-dimethyl-4,10-
dioxo-2-(3-(trifluoromethoxy)benzoyl)dodecahydro-1H-
benzo[f]isochromene-7-carboxylate (21)—Compound 21 was synthesized from
compound 11 using the general procedure and 3-(trifluoromethoxy)-phenylboronic acid to
afford 0.038 g (24.3%) isolated as a white solid, mp = 92 – 94 °C. 1H NMR (500 MHz,
CDCl3) δ 7.86 – 7.80 (m, 2H), 7.56 (t, J = 8.0 Hz, 1H), 7.48 (d, J = 7.2 Hz, 1H), 5.81 (t, J =
8.3 Hz, 1H), 5.16 – 5.09 (m, 1H), 3.72 (s, 3H), 2.78 – 2.69 (m, 1H), 2.62 (dd, J = 8.3, 13.6
Hz, 1H), 2.29 (dd, J = 7.2, 13.5 Hz, 2H), 2.19 (s, 1H), 2.18 – 2.09 (m, 5H), 1.77 (d, J = 13.2
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Hz, 1H), 1.71 – 1.53 (m, 3H), 1.47 (s, 3H), 1.09 (s, 3H). 13C NMR (126 MHz, CDCl3) δ
202.15, 193.97, 171.75, 170.72, 170.07, 150.00 (q 3JCF = 1.97), 135.62, 130.91, 127.43,
126.77, 121.56, 120.56 (q JCF = 258.18), 75.62, 75.06, 64.91, 53.48, 52.21, 49.77, 42.19,
38.03, 37.91, 35.76, 30.89, 20.79, 18.44, 16.88, 16.27. HRMS (m/z): [M+Na] calcd for
C27H29F3O9Na, 577.1661; found 577.1621. HPLC tR = 15.925 min; purity = 97.74%.
5.4.11. (2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-acetoxy-6a,10b-dimethyl-4,10-
dioxo-2-(3-(trifluoromethyl)benzoyl)dodecahydro-1H-benzo[f]isochromene-7-
carboxylate (22)—Compound 22 was synthesized from compound 11 using the general
procedure and 3-(trifluoromethyl)phenylboronic acid to afford 0.044 g (38.8%) isolated as
an off-white solid, mp = 94 – 97 °C. 1H NMR (500 MHz, CDCl3) δ 8.23 (s, 1H), 8.10 (d, J
= 7.9 Hz, 1H), 7.88 (d, J = 7.8 Hz, 1H), 7.66 (t, J = 7.8 Hz, 1H), 5.84 (t, J = 8.3 Hz, 1H),
5.16 – 5.10 (m, 1H), 3.72 (s, 3H), 2.79 – 2.70 (m, 1H), 2.61 (dd, J = 8.2, 13.6 Hz, 1H), 2.29
(dd, J = 7.5, 13.5 Hz, 2H), 2.20 (s, 1H), 2.19 – 2.08 (m, 5H), 1.77 (d, J = 13.2 Hz, 1H), 1.75
– 1.53 (m, 3H), 1.48 (s, 3H), 1.09 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 202.15, 194.16,
171.74, 170.66, 170.08, 134.49, 132.33, 132.05 (q, 2JCF =33.11 Hz), 130.87 (q, 3JCF = 3.41
Hz), 129.97, 126.18 (q, 3JCF = 3.84 Hz), 123.63 (q, JCF = 272.85 Hz), 75.56, 75.06, 64.91,
53.49, 52.22, 49.84, 42.20, 37.92, 37.86, 35.75, 30.90, 20.80, 18.44, 16.90, 16.28. HRMS
(m/z): [M+Na] calcd for C27H29F3O8Na, 561.1712; found 561.1670. HPLC tR = 5.799 min;
purity = 95.0% as determined using a Phenomenex Luna column (250 × 4.5 mm, 5 μm).
5.4.12. (2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-acetoxy-2-(furan-2-
carbonyl)-6a,10b-dimethyl-4,10-dioxododecahydro-1H-
benzo[f]isochromene-7-carboxylate (23)—Compound 23 was synthesized from
compound 11 using the general procedure and 2-furanylboronic acid to afford 0.109 g
(84.6%) isolated as a white solid, mp = 207 – 209 °C. HRMS (m/z): [M+H] calcd for
C24H29O9, 461.1812; found 461.1796. HPLC tR = 13.29 min; purity = 97.83% using 40%
CH3CN:60% H2O as the mobile phase. The 1H NMR and 13C NMR spectra were in
agreement with that previously reported.32
5.4.13. (2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-acetoxy-2-(furan-3-
carbonyl)-6a,10b-dimethyl-4,10-dioxododecahydro-1H-
benzo[f]isochromene-7-carboxylate (24)—Compound 24 was synthesized from
compound 11 using the general procedure and furan-3-boronic acid to afford 0.106 g
(67.5%) isolated as a white solid, mp = 159 – 161 °C. 1H NMR (500 MHz, CDCl3) δ 8.20
(dd, J = 0.8, 1.3 Hz, 1H), 7.44 (dd, J = 1.4, 1.9 Hz, 1H), 6.79 (dd, J = 0.8, 1.9 Hz, 1H), 5.28
(t, J = 8.0 Hz, 1H), 5.17 – 5.07 (m, 1H), 3.69 (s, 3H), 2.71 (dd, J = 5.4, 11.4 Hz, 1H), 2.54
(dd, J = 7.8, 13.8 Hz, 1H), 2.33 – 2.23 (m, 2H), 2.18 (s, 1H), 2.14 (s, 3H), 2.10 – 2.01 (m,
2H), 1.79 – 1.70 (m, 2H), 1.69 – 1.58 (m, 1H), 1.55 – 1.47 (m, 1H), 1.40 (s, 3H), 1.06 (s,
3H). 13C NMR (126 MHz, CDCl3) δ 202.05, 191.00, 171.77, 170.83, 170.06, 149.28,
144.44, 124.23, 109.43, 78.51, 75.08, 64.82, 53.52, 52.19, 50.08, 42.18, 38.25, 37.92, 35.57,
30.90, 20.80, 18.40, 16.97, 16.32. HRMS (m/z): [M+H] calcd for C24H29O9, 461.1812;
found 461.1796. HPLC tR = 5.105 min; purity = 99.67%.
5.4.14. (2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-acetoxy-6a,10b-dimethyl-4,10-
dioxo-2-(thiophene-2-carbonyl)dodecahydro-1H-benzo[f]isochromene-7-
carboxylate (25)—Compound 25 was synthesized from compound 11 using the general
procedure and 2-thiopheneboronic acid to afford 0.036 g (36.4%) isolated as an off-white
solid, mp = 188 – 190 °C. HRMS (m/z): [M+Na] calcd for C24H28O8SNa, 499.1403; found
499.1380. HPLC tR = 5.733 min; purity = 96.12%. The 1H NMR and 13C NMR spectra
were in agreement with that previously reported.32
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carboxylate (26)—Compound 26 was synthesized from compound 11 using the general
procedure and 3-thiopheneboronic acid to afford 0.081 g (74.3%) isolated as an off-white
solid, mp = 170 – 173 °C. 1H NMR (500 MHz, CDCl3) δ 8.20 (dd, J = 1.2, 2.8 Hz, 1H),
7.56 (dd, J = 1.2, 5.1 Hz, 1H), 7.37 (dd, J = 2.9, 5.1 Hz, 1H), 5.60 (t, J = 8.1 Hz, 1H), 5.17 –
5.08 (m, 1H), 3.72 (s, 3H), 2.78 – 2.67 (m, 1H), 2.61 (dd, J = 8.3, 13.7 Hz, 1H), 2.29 (dd, J =
7.5, 13.5 Hz, 2H), 2.20 (s, 1H), 2.19 – 2.06 (m, 5H), 1.71 (ddd, J = 12.5, 22.2, 34.2 Hz, 3H),
1.59 – 1.49 (m, 1H), 1.45 (s, 3H), 1.08 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 202.17,
189.63, 171.78, 171.01, 170.06, 138.44, 134.68, 127.63, 127.21, 77.09, 75.08, 64.96, 53.49,
52.19, 49.71, 42.20, 38.30, 37.92, 35.69, 30.90, 20.81, 18.44, 17.05, 16.27. HRMS (m/z):




benzo[f]isochromene-7-carboxylate (27)—Compound 27 was synthesized from
compound 11 using the general procedure and 2-benzofuranylboronic acid to afford 0.090 g
(77.2%) isolated as a white solid, mp = 228 – 232 °C. 1H NMR (500 MHz, CDCl3) δ 7.74
(d, J = 7.8 Hz, 1H), 7.71 (d, J = 0.9 Hz, 1H), 7.60 (dd, J = 0.8, 8.5 Hz, 1H), 7.55 – 7.50 (m,
1H), 7.38 – 7.31 (m, 1H), 5.75 (t, J = 8.3 Hz, 1H), 5.16 – 5.08 (m, 1H), 3.72 (s, 3H), 2.77 –
2.67 (m, 2H), 2.29 (dd, J = 7.5, 13.5 Hz, 2H), 2.25 – 2.18 (m, 2H), 2.18 – 2.11 (m, 4H), 1.81
– 1.60 (m, 4H), 1.48 (s, 3H), 1.10 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 202.15, 186.33,
171.78, 170.86, 170.04, 156.20, 149.86, 129.49, 126.98, 124.56, 123.93, 116.49, 112.90,
76.49, 75.07, 64.86, 53.49, 52.20, 49.92, 42.22, 38.22, 37.95, 35.77, 30.92, 20.80, 18.45,
16.78, 16.29. HRMS (m/z): [M+Na] calcd for C28H30O9Na, 533.1788; found 533.1797.
HPLC tR = 7.558 min; purity = 99.33%.
5.4.17. (2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-acetoxy-2-
(benzo[b]thiophene-2-carbonyl)-6a,10bdimethyl-4,10-dioxododecahydro-1H-
benzo[f]isochromene-7-carboxylate (28)—Compound 28 was synthesized from
compound 11 using the general procedure and thianaphthene-2-boronic acid to afford 0.095
g (78.8%) isolated as a white solid, mp = 127 – 130 °C. 1H NMR (500 MHz, CDCl3) δ 8.10
(s, 1H), 7.93 (d, J = 8.0 Hz, 1H), 7.88 (d, J = 8.1 Hz, 1H), 7.54 – 7.46 (m, 1H), 7.46 – 7.40
(m, 1H), 5.74 (t, J = 8.2 Hz, 1H), 5.19 – 5.09 (m, 1H), 3.72 (s, 3H), 2.79 – 2.71 (m, 1H),
2.67 (dd, J = 8.1, 13.7 Hz, 1H), 2.34 – 2.25 (m, 2H), 2.25 – 2.18 (m, 2H), 2.17 – 2.08 (m,
4H), 1.85 – 1.73 (m, 2H), 1.73 – 1.63 (m, 1H), 1.63 – 1.53 (m, 1H), 1.48 (s, 3H), 1.09 (s,
3H). 13C NMR (126 MHz, CDCl3) δ 202.22, 190.04, 171.79, 170.84, 170.01, 143.20,
139.72, 139.13, 131.67, 128.45, 126.81, 125.56, 123.11, 76.90, 75.08, 64.83, 53.46, 52.19,
49.81, 42.21, 38.59, 37.90, 35.75, 30.91, 20.79, 18.44, 16.98, 16.29. HRMS (m/z): [M+Na]




benzo[f]isochromene-7-carboxylate (29)—Compound 29 was synthesized from
compound 11 using the general procedure and 1-benzothiophen-3-ylboronic acid to afford
0.065g (23.3%) isolated as an off-white solid, mp = 133 – 136 °C. 1H NMR (500 MHz,
CDCl3) δ 8.72 (d, J = 7.9 Hz, 1H), 8.43 (s, 1H), 7.89 (d, J = 7.9 Hz, 1H), 7.56 – 7.50 (m,
1H), 7.46 (dd, J = 4.1, 11.1 Hz, 1H), 5.77 (t, J = 8.2 Hz, 1H), 5.18 – 5.08 (m, 1H), 3.72 (s,
3H), 2.77 – 2.70 (m, 1H), 2.65 (dd, J = 8.3, 13.7 Hz, 1H), 2.29 (dd, J = 7.2, 13.5 Hz, 2H),
2.26 – 2.18 (m, 2H), 2.13 (d, J = 16.9 Hz, 4H), 1.84 – 1.53 (m, 4H), 1.47 (s, 3H), 1.09 (s,
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3H). 13C NMR (126 MHz, CDCl3) δ 202.27, 190.09, 171.80, 171.13, 170.04, 139.79,
139.45, 136.99, 131.61, 126.46, 126.16, 125.67, 122.57, 76.76, 75.12, 64.94, 53.50, 52.19,
49.68, 42.23, 38.51, 37.97, 35.68, 30.91, 20.79, 18.46, 17.06, 16.26. HRMS (m/z): [M+H]
calcd for C28H31O8S, 527.1740; found 527.1742. HPLC tR = 6.64 min; purity = 96.84%.
5.4.19. (2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-acetoxy-2-((Z)-but-2-enoyl)-6a,
10b-dimethyl-4,10-dioxododecahydro-1H-benzo[f]isochromene-7-carboxylate
(30)—Compound 30 was synthesized from compound 11 using the general procedure and
cis-1-propen-1-ylboronic acid to afford 0.195 g (72.7%) isolated as a white solid, mp = 153
– 155 °C. 1H NMR (500 MHz, CDCl3) δ 6.48 (dq, J = 7.3, 11.4 Hz, 1H), 6.33 (dd, J = 1.7,
11.4 Hz, 1H), 5.19 – 5.11 (m, 1H), 4.92 (dd, J = 7.4, 9.3 Hz, 1H), 3.72 (s, 3H), 2.73 (dd, J =
5.8, 11.1 Hz, 1H), 2.52 (dd, J = 7.4, 13.7 Hz, 1H), 2.33 – 2.25 (m, 2H), 2.17 (dd, J = 2.0, 7.0
Hz, 7H), 2.10 (dd, J = 3.4, 14.3 Hz, 1H), 2.00 (dd, J = 3.2, 11.8 Hz, 1H), 1.76 (dd, J = 3.3,
13.3 Hz, 1H), 1.65 (dd, J = 12.6, 27.3 Hz, 1H), 1.59 – 1.48 (m, 2H), 1.38 (s, 3H), 1.08 (s,
3H). 13C NMR (126 MHz, CDCl3) δ 201.98, 196.49, 171.76, 170.83, 170.10, 149.06,
122.82, 79.95, 75.10, 64.78, 53.60, 52.20, 50.37, 42.21, 38.05, 37.94, 35.56, 30.91, 20.81,
18.40, 16.76, 16.43, 16.35. HRMS (m/z): [M+Na] calcd for C23H30O8Na, 457.1838; found
457.1859. HPLC tR = 15.253 min; purity = 95.43% using 40% CH3CN:60% H2O as the
mobile phase.
5.5. Preparation of (2S,4aR,6aR,7R,9S,10aS,10bR)-methyl 9-acetoxy-2-(furan-2-yl)-6a,10b-
dimethyl-4,10-di-oxododecahydro-1H-benzo[f]isochromene-7-carboxylate (31)
Alkene 30 (0.108 g, 0.249 mmol) was dissolved in bromobenzene (15 mL) followed by the
addition of selenium (IV) oxide (0.083 g, 0.746 mmol). Reaction mixture was heated at
160°C and monitored by TLC. The solvent was evaporated in vacuo and the resulting
residue purified by flash column chromatography on silica gel using mixtures of EtOAc/n-
hexanes and triturated in EtOAc/n-hexanes to yield 0.195 g (18.1%) of 31 as a white solid,
mp 198 – 200 °C; 1H NMR (500 MHz, CDCl3) δ 7.39 (dd, J = 0.8, 1.7 Hz, 1H), 6.36 – 6.31
(m, 2H), 5.52 (dd, J = 5.6, 11.6 Hz, 1H), 5.18 – 5.11 (m, 1H), 3.73 (s, 3H), 2.81 – 2.72 (m,
1H), 2.45 (dd, J = 5.6, 13.6 Hz, 1H), 2.36 – 2.27 (m, 2H), 2.23 (s, 1H), 2.20 – 2.12 (m, 5H),
1.93 – 1.85 (m, 1H), 1.83 – 1.76 (m, 1H), 1.71 – 1.59 (m, 2H), 1.44 (s, 3H), 1.11 (s,
3H). 13C NMR (126 MHz, CDCl3) δ 202.17, 171.79, 171.07, 170.20, 151.41, 143.38,
110.66, 109.27, 75.27, 72.01, 64.30, 53.78, 52.21, 51.25, 42.33, 40.52, 38.36, 35.51, 30.95,
20.79, 18.36, 16.53, 15.28. HRMS (m/z): [M+Na] calcd for C23H28O8Na, 455.1682; found,
455.1695. HPLC tR = 24.103 min; purity = 97.44% using 40% CH3CN:60% H2O as the
mobile phase.
5.6. Opioid Binding Assay.50
Recombinant Chinese Hamster Ovary (CHO) cells (hMOP-CHO, hDOP-CHO and hKOP-
CHO) were produced by stable transfection with the respective human opioid receptor
cDNA, and provided by Dr. Larry Toll (SRI International, CA). The cells were grown on
plastic flasks in DMEM (90%) (hDOP-CHO and hKOP-CHO) or DMEM/ F-12 (45%/ 45%)
medium (hMOP-CHO) containing 10% FetalClone II (HyClone) and Geneticin (G-418:
0.10–0.2 mg/ml) (Invitrogen) under 95% air/5% CO2 at 37° C. Cell monolayers were
harvested and frozen at −80 °C. The hKOP-CHO, hMOP-CHO and hDOP-CHO cells are
used for opioid binding experiments. For the [35S]GTP-γ-S binding experiments, we use
hKOP-CHO and hMOP-CHO cells for assaying KOP and MOP receptor function. We use
the NG108–15 neuroblastoma×glioma cell for the DOP [35S]GTP-γ-S binding assay. We
used [3H][D-Ala2-MePhe4,Gly-ol5]enkephalin ([3H]DAMGO, SA=44–48 Ci/mmol) to label
MOP, [3H][D-Ala2,D-Leu5]enkephalin ([3H]DADLE, SA=40–50 Ci/mmol) to label DOP
receptors and [3H](−)-U69,593 (SA=50 Ci/mmol) to label KOP receptor binding sites. On
the day of the assay, cell pellets were thawed on ice for 15 minutes then homogenized with a
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polytron in 10 mL/pellet of ice-cold 10mM Tris-HCl, pH 7.4. Membranes were then
centrifuged at 30,000 × g for 10 minutes, resuspended in 10 ml/pellet ice-cold 10mM Tris-
HCl, pH 7.4 and again centrifuged 30,000 × g for 10 min. Membranes were then
resuspended in 25 °C 50 mMTris-HCl, pH 7.4 (~100 mL/pellet hMOP-CHO, 50 ml/pellet
hDOP-CHO and 120 ml/pellet hKOP-CHO). All assays took place in 50 mMTris-HCl, pH
7.4, with a protease inhibitor cocktail [bacitracin (100 μg/ mL, bestatin (10 μg/ mL),
leupeptin (4 μg/mL) and chymostatin (2 μg/mL)], in a final assay volume of 1.0 mL. All
drug dilution curves were made up with buffer containing 1 mg/mL BSA. Nonspecific
binding was determined using 20 μM levallorphan ([3H]DAMGO and [3H]DADLE) and 1
μM (−)-U69,593 (for [3H]U69,593 binding). [3H]Radioligands were used at ~ 2 nM
concentrations. Triplicate samples were filtered with Brandel Cell Harvesters (Biomedical
Research & Development Inc., Gaithersburg, MD), over Whatman GF/B filters, after a 2 hr
incubation at 25 °C. The filters were punched into 24-well plates to which was added 0.6 ml
of LSC-cocktail (Cytoscint). Samples were counted, after an overnight extraction, in a
Trilux liquid scintillation counter at 44% efficiency. Opioid binding assays had ~30 μg
protein per assay tube. Inhibition curves were generated by displacing a single concentration
of radioligand by 10 concentrations of drug.
5.7. [35S]GTP-γ-S Binding Assay
The [35S]GTP-γ-S assays were conducted as described elsewhere.50 In this description,
buffer “A” is 50 mM Tris-HCl, pH 7.4, containing 100 mM NaCl, 10 mM MgCl2, 1 mM
EDTA and buffer “B” is buffer A plus 1.67 mM DTT and 0.15% BSA. On the day of the
assay, cells were thawed on ice for 15 min and homogenized using a polytron in 50 mM
Tris-HCl, pH 7.4, containing 4 μg/mL leupeptin, 2 μg/mL chymostatin, 10 μg/mL bestatin
and 100 μg/mL bacitracin. The homogenate was centrifuged at 30,000 × g for 10 min at 4
°C, and the supernatant discarded. The membrane pellets were resuspended in buffer B and
used for [35S]GTP-γ-S binding assays. [35S]GTP-γ-S binding was determined as described
previously. Briefly, test tubes received the following additions: 50 μL buffer A plus 0.1%
BSA, 50 μL GDP in buffer A/0.1% BSA (final concentration = 40 μM), 50 μL drug in
buffer A/0.1% BSA, 50 μL [35S]GTP-γ-S in buffer A/0.1% BSA (final concentration = 50
pM), and 300 μL of cell membranes (50 μg of protein) in buffer B. The final concentrations
of reagents in the [35S]GTP-γ-S binding assays were: 50 mM Tris-HCl, pH 7.4, containing
100 mM NaCl, 10 mM MgCl2, 1 mM EDTA, 1 mM DTT, 40 μM GDP and 0.1% BSA.
Incubations proceeded for 3 hr at 25 °C. Nonspecific binding was determined using GTP-γ-
S (40 μM). Bound and free [35S]GTP-γ-S were separated by vacuum filtration (Brandel)
through GF/B filters. The filters were punched into 24-well plates to which was added 0.6
mL LSC-cocktail (Cytoscint). Samples were counted, after an overnight extraction, in a
Trilux liquid scintillation counter at 27% efficiency.
5.8. Fluorescent Ca2+ Mobilization Assay.51
All cells were maintained in F-12 nutrient medium (Ham), supplemented with 10% fetal
bovine serum (FBS), 1% penicillin and streptomycin (p/s), and 0.2% normocin. Cell culture
supplies were from Invitrogen (Carlsbad, CA) unless otherwise specified. CHO cells stably
expressing KOP R-Gαq16 were removed from their flasks using Versene and quenched with
the Ham media, centrifuged and re-suspended in media. Cells were counted with a
Cellometer Auto T4 (Nexcelom Bioscience, Lawrence, MA) and 30,000 cells were
transferred to each well of a black Costar 96-well optical bottom plate (Corning
Corporation, Corning, NY). Each plate was incubated at 37 °C overnight to confluence. The
culture media was removed from the plates and cells were subsequently loaded with a
fluorescent calcium probe (Calcium 5 dye, Molecular Devices, Sunnyvale, CA) in an HBSS-
based buffer containing 20 mM HEPES, 0.25% BSA, 1% DMSO, and 10 μMprobenecid
(Sigma) in a total volume of 225 μL. Cells were incubated at 37°C for 1 h and then
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stimulated with DAMGO, U69,593 or test compounds at various concentrations using a
Flexstation 3 plate-reader, which automatically added 25 μL of the compounds at 10X
concentration to each well after reading baseline values for ~17 sec. Agonist-mediated
change in fluorescence (485 nm excitation, 525 nm emission) was monitored in each well at
1.52 sec intervals for 60 sec and reported for each well. Data were collected using Softmax
version 4.8 (MDS Analytical Technologies) and analyzed using Prism software (GraphPad,
La Jolla, CA). Nonlinear regression analysis was performed to fit data and obtain maximum
response max), EC50, correlation coefficient (r2) and other parameters. All experiments were
performed at least 3 times to ensure reproducibility and data reported as mean ± standard
error, unless noted otherwise.
5.9. Neuroendocrine biomarker assay.45
Chair-trained male rhesus monkeys (Macaca mulatta) were tested after extensive prior
exposure to the experimental situation. Approximately 15 min following catheter placement,
two baseline blood samples of approximately 2 mL were collected, 5 min apart from each
other (defined as −10 and −5 min, relative to the onset of dosing), and kept at room
temperature until the time of spinning (3000 rpm at 4 °C) and serum separation.
Experiments were carried out with a cumulative dosing procedure, where doses of 1 or 3
were administered i.v. in increasing 0.5 log unit steps, every 20 min, and a blood sample was
taken 15 min after each dose. Data for 1 were from a previous determination under identical
experimental conditions.45 Serum samples were kept at −40 °C until the time of analysis,
typically within 2 weeks of collection. Samples were analyzed in duplicate with a standard
human prolactin immunoradiometric kit (Siemens Medical Solutions Diagnostics, Los
Angeles CA), following manufacturer's instructions. Procedures were reviewed and
approved by the Rockefeller University Animal Care and Use Committee, in accordance
with the Guide on the Care and Use of Animals (National Academy Press, 1996). Data are
presented graphically as ng/ml (i.e., drug effect – mean pre-injection baseline per subject).
Linear regression analyses were calculated from mean dose-effect curve points spanning the
ED50 point.
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Structures of salvinorin A (1) and U50,488 (2).
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aReagents and Conditions: a) 2,4,4,6-Tetrabromo-2,5-cyclohexadienone, CH2Cl2, 130 °C,
30 min MW.
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aReagents and Conditions: a) NaBH4, I2, THF, 0 °C; b) PBr3, THF, 0 °C; c) 1-phenyl-1H-
tetrazole-5-thiol, Et3N, H2O2, (NH4)6Mo7O24·4H2O, CH2Cl2; d) 7, KHMDS, THF, −78 °C
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aReagents and Conditions: a) CDMT, NMM, thiophenol, CH2Cl2; b) Appropriate boronic
acid, copper thiophene-2-carboxylate (CuTC), Pd(dba)2, P(OEt)3, THF
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aReagents and Conditions: a) cis-1-Propen-1-ylboronic acid, CuTC, Pd(dba)2, P(OEt)3,
THF; b) SeO2, Bromobenzene, reflux
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Dose-effect curve in a neuroendocrine biomarker assay for the effects of i.v.1 and 12-epi-1
(3) on serum prolactin levels in male subjects. Data for 1 were from a previous
determination under identical experimental conditions.45 Abscissa, dose of 1 or 3. Ordinate,
serum prolactin levels, expressed as change from individual preinjection baseline
( nanograms per milliliter; mean ±SEM).
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Table 1
Opioid receptor binding affinities of neoclerodanes 1, 3, 9, 10, and 12 – 31.
Ki± SD, nM
Cmpd MOP DOP KOP
1 

































































































































































Ki values (±SD) were determined from full dose-response curves (n=3) as described in methods.
b
Results are showing the percent of control produced by the 1 μM test drug.
c
Results are showing the percent of control produced by the 10 μM test drug.
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Table 2
Stimulation of [35S]GTP-γ-S binding to human KOP receptors.




1 40 ± 6 124 ± 6
3 720 ± 97 109 ± 4
9 1,370 ± 180 105 ± 4
12 2,280 ± 550 74 ± 6
19 730 ± 90 92 ± 4
23 2,130 ± 310 92 ± 4
25 1,630 ± 230 95 ± 4
26 620 ± 50 88 ± 2
31 140 ± 10 104 ± 2
a
EC50 = Effective concentration for 50% maximal response.
b
Emax is % which compound stimulates binding compared to (−)-U50,488 at KOP receptors.
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Table 3
Opioid receptor activity measured in the fluorescent Ca2+ mobilization assay.






c 12.5 ± 5.4 100
1 
d 6.11 ± 0.04 97 ± 5
19 
c 75.4 ± 21 97 ± 2
31 
c 12.2 ± 4.4 97± 8
a
EC50 = Effective dose for 50% maximal response.
b





Bioorg Med Chem. Author manuscript; available in PMC 2013 May 01.
